EA200901474A1 - Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе - Google Patents

Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе

Info

Publication number
EA200901474A1
EA200901474A1 EA200901474A EA200901474A EA200901474A1 EA 200901474 A1 EA200901474 A1 EA 200901474A1 EA 200901474 A EA200901474 A EA 200901474A EA 200901474 A EA200901474 A EA 200901474A EA 200901474 A1 EA200901474 A1 EA 200901474A1
Authority
EA
Eurasian Patent Office
Prior art keywords
various crystal
ilsulphonylmochevanium
ilsulphonylmochevan
salts
chlorthiophen
Prior art date
Application number
EA200901474A
Other languages
English (en)
Russian (ru)
Inventor
Эмма Шарп
Лоуиса Джейн Кеган
Анджали Панди
Цзуань Ван
Маттью Нидер
Волинь Хуан
Original Assignee
Портола Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Портола Фармасьютиклз, Инк. filed Critical Портола Фармасьютиклз, Инк.
Publication of EA200901474A1 publication Critical patent/EA200901474A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200901474A 2007-05-02 2008-05-02 Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе EA200901474A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02
PCT/US2008/062584 WO2008137809A2 (en) 2007-05-02 2008-05-02 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
EA200901474A1 true EA200901474A1 (ru) 2010-04-30

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901474A EA200901474A1 (ru) 2007-05-02 2008-05-02 Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе

Country Status (18)

Country Link
US (1) US20090042916A1 (enExample)
EP (1) EP2076510A2 (enExample)
JP (1) JP2010526105A (enExample)
KR (1) KR20100020455A (enExample)
CN (1) CN101720324A (enExample)
AU (1) AU2008247457A1 (enExample)
BR (1) BRPI0810800A2 (enExample)
CA (1) CA2686221A1 (enExample)
CO (1) CO6241155A2 (enExample)
EA (1) EA200901474A1 (enExample)
EC (1) ECSP099779A (enExample)
GT (1) GT200900282A (enExample)
IL (1) IL201829A0 (enExample)
MA (1) MA31397B1 (enExample)
MX (1) MX2009011836A (enExample)
TN (1) TN2009000452A1 (enExample)
WO (1) WO2008137809A2 (enExample)
ZA (1) ZA200907493B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
WO2019126557A1 (en) 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
PL1668002T3 (pl) * 2003-10-03 2010-02-26 Portola Pharm Inc 2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20090048216A1 (en) * 2007-05-02 2009-02-19 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Also Published As

Publication number Publication date
JP2010526105A (ja) 2010-07-29
TN2009000452A1 (en) 2011-03-31
CO6241155A2 (es) 2011-01-20
EP2076510A2 (en) 2009-07-08
ZA200907493B (en) 2010-07-28
MX2009011836A (es) 2010-05-20
CN101720324A (zh) 2010-06-02
BRPI0810800A2 (pt) 2014-10-29
GT200900282A (es) 2010-05-21
CA2686221A1 (en) 2008-11-13
MA31397B1 (fr) 2010-05-03
IL201829A0 (en) 2010-06-16
AU2008247457A1 (en) 2008-11-13
ECSP099779A (es) 2010-01-29
US20090042916A1 (en) 2009-02-12
WO2008137809A3 (en) 2009-01-22
WO2008137809A2 (en) 2008-11-13
KR20100020455A (ko) 2010-02-22

Similar Documents

Publication Publication Date Title
ATE517882T1 (de) Chinolinderivate
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201270339A1 (ru) Замещенные производные ксантина
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren